Field report E-7 / K6
Filed from the territory
FDA rejects Summit’s ivonescimab over survival evidence
The FDA rejected Summit Therapeutics’ ivonescimab after the Phase 3 HARMONi trial improved progression-free survival but failed to show a statistically significant overall-survival benefit.
- Grid
- E-7 / K6
- Surveyed
- November 20, 2026
- Reading
- 3 min read
- Correspondent
- Priya Raman
Field notes
- The FDA rejected ivonescimab after the Phase 3 HARMONi trial missed statistical significance on overall survival.
- A longer-term post-hoc analysis showed an overall-survival hazard ratio of 0.76 in three populations.
- Treatment-related discontinuations were 7.3% for ivonescimab versus 5.0% for placebo.
- AstraZeneca invested $2 billion for roughly 12% of Summit last month.
- Summit’s 2022 license from Akeso was valued at as much as $5 billion.
By Priya Raman
The FDA has rejected Summit Therapeutics’ lung cancer drug ivonescimab in its present form, saying the company failed to establish substantial evidence of effectiveness without a statistically significant improvement in overall survival.
The complete response letter—an FDA decision that an application is not approvable as submitted—blocks the current application for ivonescimab with platinum-containing chemotherapy. Summit sought approval for patients with locally advanced or metastatic non-small cell lung cancer who had already received an EGFR tyrosine kinase inhibitor, a targeted cancer treatment.
Summit disclosed the rejection on Sunday in a filing with the Securities and Exchange Commission, or SEC.
What did the FDA reject, and why?
According to Summit, the FDA concluded that a progression-free survival benefit, meaning a delay in cancer worsening or death, did not support a positive benefit-risk profile without a statistically significant overall-survival benefit.
The agency said substantial evidence of effectiveness was not established on that basis. That reasoning matters because HARMONi, the global Phase 3 trial underpinning the application, produced mixed results across its two primary endpoints.
What did the HARMONi trial show?
HARMONi compared ivonescimab plus chemotherapy with placebo plus chemotherapy. Its primary endpoints were progression-free survival and overall survival, and it met the progression-free survival endpoint.
In the primary overall-survival analysis, the ivonescimab combination produced a positive trend that fell short of statistical significance, Summit said. The result therefore did not provide the survival evidence the FDA required.
A post-hoc analysis, meaning a comparison performed after the main analysis, showed an overall-survival hazard ratio of 0.76, a measure of relative event rates. The company reported the same figure in the full population, Asian patients and Western patients.
Summit also said no FDA-approved regimen had demonstrated a statistically significant overall-survival benefit in this patient setting. That company claim does not change the FDA’s finding that the submitted application lacked the required effectiveness evidence.
What did the safety results show?
Summid reported the following treatment-related safety findings from HARMONi:
- Discontinuations: 16 patients, or 7.3%, stopped ivonescimab because of treatment-related adverse events, compared with 11 patients, or 5.0%, in the placebo arm.
- Deaths: Four patients, or 1.8%, in the ivonescimab arm and five patients, or 2.3%, in the chemotherapy-only arm died from treatment-related adverse events.
- Safety assessment: Summit said the trial showed no new safety signals, meaning no previously unidentified safety pattern emerged.
Can Summit continue developing ivonescimab?
“We are disappointed for patients and their families awaiting additional treatment options in this setting,” Robert W. Duggan, Summit’s chairman and co-chief executive, said in a statement.
Duggan said the company’s belief in ivonescimab remained unchanged and that Summit would continue its clinical development programme. The company is developing the drug in lung, colorectal, urothelial and renal cell cancers.
Summit said ivonescimab was not approved by any regulator in its licensed territories, including the United States and Europe. It also said no PD-1 x VEGF bispecific antibodies, a dual-target drug class, had been approved in the United States.
Akeso invented ivonescimab, which was first approved in China in May 2024. Summit obtained rights to the drug from Akeso in 2022 through an agreement valued at as much as $5 billion covering the United States, Canada, Europe and Japan, according to MarketWatch.
AstraZeneca completed a $2 billion equity investment in Summit last month, giving it a roughly 12% stake. The structure left Summit with full development and commercial rights to ivonescimab rather than placing control of the asset with AstraZeneca.
The investment also came with a clinical collaboration to test AstraZeneca’s sonesitatug vedotin alongside ivonescimab. Summit therefore retains responsibility for the drug’s development and commercialisation while drawing on AstraZeneca’s $2 billion backing and a combination trial.
For now, the FDA rejection leaves the central regulatory question unresolved: HARMONi demonstrated a progression-free survival benefit, but its primary overall-survival result did not meet the agency’s threshold for approval.
via qz.com (Source)
More from Priya Raman
Show full bio
Senior reporter covering technology and product news in corporate strategy and chief-executive leadership at CEO Frontier.
478 articles
Adjacent sheets
- Merck KGaA drops Silence heart drug after rival trial fails
- Merck CEO Rob Davis expects cancer vaccine turnaround to shrink from six weeks
- AstraZeneca weighs cancer vaccines as Phase 3 data emerge
- Astellas CEO Bets on 5-Year Plan to Outrun Xtandi Patent Cliff
- SELLAS Vaccine Cuts Death Risk 41% as Patent Expiry Starts in 2026